Trials / Active Not Recruiting
Active Not RecruitingNCT02944500
Saxenda: Underlying Mechanisms and Clinical Outcomes
- Status
- Active Not Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Beth Israel Deaconess Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this protocol is to investigate the effect of treatment with the study drug Liraglutide, a GLP-1 receptor agonist, on centers of the brain that control appetite and food intake.
Detailed description
The effect of treatment with the study drug Liraglutide, a recently discovered GLP-1 receptor agonist, on centers of the brain that control appetite and food intake will be studied in detail.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | liraglutide | |
| OTHER | Placebo |
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2026-06-01
- Completion
- 2026-06-01
- First posted
- 2016-10-26
- Last updated
- 2025-03-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02944500. Inclusion in this directory is not an endorsement.